NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
See the press release on Business Wire
See the press release on EIN Newswire
See the press release on EIN Newswire